Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Sofia PitsigavdakiMyrto NikoloudakiPanagiotis GarantziotisEttore SilvagniArgyro RepaAntonio MarangoniIrini FlouriNestor AvgoustidisKonstantinos ParperisAntonis FanouriakisMarcello GovoniProdromos SidiropoulosDimitrios T BoumpasAlessandra BortoluzziGeorge K BertsiasPublished in: Annals of the rheumatic diseases (2024)
In moderate-to-severe SLE, sustained DORIS/LLDAS for at least 6 months is sufficient, while attainment for at least 24 months ensures higher specificity for damage-free progression, thus facilitating treat-to-target strategies and clinical trials. Arthritis and skin disease represent unmet therapeutic needs that could benefit from novel biologics.
Keyphrases
- clinical trial
- systemic lupus erythematosus
- study protocol
- oxidative stress
- healthcare
- disease activity
- rheumatoid arthritis
- high intensity
- early onset
- phase ii
- palliative care
- phase iii
- randomized controlled trial
- quality improvement
- soft tissue
- open label
- drug induced
- chronic pain
- double blind
- affordable care act
- placebo controlled